Repros is engaged in the development of pharmaceutical products that address conditions of the male and female reproductive systems. Proellex, the Company's lead compound, is a selective blocker of the progesterone receptor which is being developed as an oral treatment for both uterine fibroids and endometriosis. Uterine fibroids affect numerous women of childbearing age in the U.S. and results in a significant number of hysterectomies each year. Endometriosis is a condition that affects approximately 5.5 million women in the U.S. and Canada.

Contact Information

2408 Timberloch Place
Suite B-7
The Woodlands, TX 77380

tel: 281-719-3400
fax: 281-719-3446


Investor Relations



Exchange: NASDAQ
Industry: Biotechnology
Market Cap: $118.6M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.